Nonmelanoma skin cancer was the most frequent and recurrent second malignancy; prior nonmelanoma skin cancer conferred ...
Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...
Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...
This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited ...
The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...
A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...
AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains. When high-efficacy drugs stop holding relapsing ...
In the final episode, 'Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care,' the panelists ...
Survivorship care and patient follow-up, being pivotal to managing treatment plans for patients with breast cancer, were key ...
INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting ...
Prevalence is high (≈1:200–300 C282Y homozygotes; ≈1:8–10 carriers), but penetrance is incomplete, complicating broad screening policy and payer coverage decisions. Nonspecific presentations (fatigue, ...
Harrison noted that responses were observed across calreticulin mutation types and among patients with additional mutations, with minimal toxicity reported to date. She concluded by describing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results